THAC, The Healthy Aging Company, is a French and US-based privately-owned biopharmaceutical company which has the ambition to develop a range of first-in-class drug candidates targeting T2DM and its complications.


♦ Its pipeline could lead to potential real game changers for patient care and disease management. THAC is primarily focused on Type 2 Diabetes Mellitus, a condition with still unmet medical needs.

THAC envisions that by fighting insulin resistance, the root cause of T2DM, major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as peripheral neuropathy (e.g. diabetic foot wounds, amputations).

THAC drug candidates have a unique and innovative mechanism of action that targets oxidation and inflammation, which restores the composition of microbiota, and the insulin sensitivity.

THAC drug candidates are intended to delay disease progression, improve patient’s quality of life, delay premature death and prevent T2DM complications ; peripheral neuropathy is a severe complication for which there is no treatment available; e.g., diabetic foot wounds and amputations.

THAC builds a pipeline of game changer therapies and develops a range of first-in-class drugs for T2DM patient’s care and disease management

> THAC is a clinical stage company focused on research, development and commercialization of game changer therapies for T2DM and speed up its preclinical and clinical study programs by strongly invest.

> The unique and innovative mechanism of action of ALF-5755 allows to restore insulin resistance, the root cause of T2DM disease, as well as the microbiota composition. This mechanism of action and all its scientific and preclinical results already observed are the object of publications in high level scientific journals.

> Regulatory preclinical studies were performed and the safety in humans was confirmed in a successful first-in-man phase I clinical study.

> THAC is now in the process of launching a phase II clinical study. In parallel, we anticipate phase I bridge studies with different formulations, specifically designed to restore gut microbiota composition and to further improve T2DM patient management.

> THAC concluded an exclusive global licensing agreement with a partner for the commercialization and development rights of the molecule in this indication. THAC will conclude new partnerships with biopharmaceutical industry leaders at the end of phase II studies.

ALF-5755, a First-in-Class drug candidate for the treatment of T2DM and its complications

♦ Human recombinant protein (17 kDa) derived from REG3a

♦ Anti-Microbial Protein (AMP) C-type lectin (binding to sugar and extracellular matrix)- Against Gram+ bacteria

♦ Secreted protein by Paneth cells (intestine)

♦ Expression driven by IL6 and inflammation

A main driver of the enteric innate immunity contributing to a balanced decrease of pathogens and increase of gut commensal bacteria

A unique and innovative mode of action

ALF-5755 has a unique and innovative mechanism of action

ALF-5755, the active ingredient of THAC drug candidates, fight the insulin resistance, which is the root cause of T2DM and restores the microbiota compositio thanks to its unique  α-inflammation & ROS scavenger effects.

Moreover, ALF-5755 has other potential indications in age-related diseases.

ALF-5755 unique and innovative mechanism of action and the scientific and clinical results already observed are the object of publications in high level scientific journals.

A unique local action to restore the microbiota composition for a systemic benefit


♦ Numerous studies have demonstrated the role of the microbiota in the development of chronic inflammatory diseases such as inflammatory diseases of the bowel (IBD) but also metabolic syndrome, type II diabetes, obesity, cardiovascular diseases (Ferreira et al., J. Immunol. Research 2014) or neurological diseases such as Alzheimer’s disease (Kowalski et al., J. Neurogastroenterology and Motility 2019).


ALF-5755, through its local anti-microbial and ROS-scavenger effects, restores the composition of the microbiota by increasing anti-inflammatory anaerobic bacteria. Then it restores the the integrity of the intestinal barrier, it decreases circulating pro-inflammatory compounds, and it restore the redox balance. As a consequence, it restores the insulin sensitivity – Darnaud M.,  Bréchot C. et al. Gastroenterology 2018.


♦ The local activity of ALF-5755 on the microbiota is complementary to its systemic mechanism of action on other extracellular matrixes. These two convergent mechanisms of action address chronic inflammation and oxidation both involved in various age-related diseases such as type II diabetes.

A strong patents portfolio and know-how for a robust protection

Several family patents are have already een granted to protect THAC drug candidates in different diseases and territories,  focused on insulin resistance and microbiota composition. Other patents are pending.

♦ A solid know-how has been acquired for ALF-5755 production.

A unique combination of effects which lead to restore the insulin sensitivity, the root cause of T2DM disease.

shutterstock_1446139847 (2)
shutterstock_1445216525 (2)

ALF5755 binds the fibrin molecule in the extracellular matrix in an environment of inflammation (Moniaux ., Bréchot C., PLoS 2016).

This binding leads to a local anti-inflammation and ROS-scavenger effects which induce intracellular signalling pathway, the activation of the receptor of insulin and the receptor of glucose.

By this way, ALF-5755 fights the insulin resistance with a unique and innovative mechanism of action.